{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:42Z","timestamp":1787977062331,"version":"build-2784847793"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die wechselseitigen Beziehungen von Diabetes mellitus, kardiovaskul\u00e4rer Erkrankung und Herzinsuffizienz erfordern einen ganzheitlichen Behandlungsansatz. Bei der Erstmanifestation einer kardiovaskul\u00e4ren Erkrankung sollte stets ein aktives Screening auf Diabetes mellitus erfolgen. Umgekehrt muss bei bereits diagnostiziertem Diabetes mellitus die kardiovaskul\u00e4re Risikostratifizierung unter Ber\u00fccksichtigung aller relevanten Risikofaktoren, Biomarker sowie des klinischen Gesamtbildes erfolgen und um ein optimales individuell abgestimmtes Management zu gew\u00e4hrleisten. Ein interdisziplin\u00e4res Vorgehen, das diabetologische, kardiologische und weitere Fachkompetenzen integriert, ist unerl\u00e4sslich, um kardiovaskul\u00e4re Komplikationen bei Menschen mit Diabetes fr\u00fchzeitig zu erkennen und effektiv zu behandeln.<\/jats:p>","DOI":"10.1007\/s00508-025-02667-8","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:48Z","timestamp":1779315168000},"page":"234-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiovaskul\u00e4re Erkrankungen und Herzinsuffizienz bei Diabetes: Diagnostik und Management (Update 2026)","Cardiovascular diseases and heart failure in diabetes: diagnostics and management (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Matthias W.","family":"Heinzl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Steinwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Falkensammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steinmaurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph H.","family":"Saely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Hoppichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Wascher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Winhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Paulweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"F\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stulnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"1","key":"2667_CR1","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care. 2025;48(1):S207\u2013S38.","journal-title":"Diabetes Care"},{"issue":"2","key":"2667_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto\u00a0E, et\u00a0al. Diabetes as a\u00a0cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2):25\u201332.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"2667_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S2213-8587(23)00223-1","volume":"11","author":"C Emerging Risk Factors","year":"2023","unstructured":"Emerging Risk Factors\u00a0C. Life expectancy associated with different ages at diagnosis of type\u00a02 diabetes in high-income countries: 23\u00a0million person-years of observation. Lancet Diabetes Endocrinol. 2023;11(10):731\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2667_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani\u00a0A, et\u00a0al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med. 2018;379(7):633\u201344.","journal-title":"N Engl J Med"},{"issue":"39","key":"2667_CR5","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx\u00a0N, et\u00a0al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart\u00a0J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"e00076","key":"2667_CR6","first-page":"3","volume":"2","author":"W Weng","year":"2019","unstructured":"Weng\u00a0W, et\u00a0al. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a\u00a0large type\u00a02 diabetes population in the United States. Endocrinol Diabetes Metab. 2019;2(e00076):3.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"9","key":"2667_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"RS Kondapally Seshasai","year":"2011","unstructured":"Kondapally Seshasai\u00a0RS, et\u00a0al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N\u00a0Engl J Med. 2011;364(9):829\u201341.","journal-title":"N Engl J Med"},{"issue":"5","key":"2667_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jacc.2021.05.004","volume":"78","author":"MC Honigberg","year":"2021","unstructured":"Honigberg\u00a0MC, et\u00a0al. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. J\u00a0Am Coll Cardiol. 2021;78(5):453\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2667_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2337\/dc24-1516","volume":"48","author":"T Ohkuma","year":"2025","unstructured":"Ohkuma\u00a0T, et\u00a0al. Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial. Diabetes Care. 2025;48(2):279\u201384.","journal-title":"Diabetes Care"},{"issue":"11","key":"2667_CR10","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P Gaede","year":"2016","unstructured":"Gaede\u00a0P, et\u00a0al. Years of life gained by multifactorial intervention in patients with type\u00a02 diabetes mellitus and microalbuminuria: 21\u00a0years follow-up on the Steno\u20112 randomised trial. Diabetologia. 2016;59(11):2298\u2013307.","journal-title":"Diabetologia"},{"issue":"6","key":"2667_CR11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/dom.13243","volume":"20","author":"K Khunti","year":"2018","unstructured":"Khunti\u00a0K, Kosiborod\u00a0M, Ray\u00a0KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018;20(6):1337\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2667_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2007.11.020","volume":"199","author":"CH Saely","year":"2008","unstructured":"Saely\u00a0CH, et\u00a0al. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. Atherosclerosis. 2008;199(2):317\u201322.","journal-title":"Atherosclerosis"},{"key":"2667_CR13","doi-asserted-by":"crossref","unstructured":"Heinzl MW, et\u00a0al. Intrahospital Prevalence of Diabetes and Prediabetes in Medical Departments in Upper Austria. J\u00a0Clin Med. 2025;14(11).","DOI":"10.3390\/jcm14113668"},{"issue":"7","key":"2667_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00125-016-3948-x","volume":"59","author":"L Huo","year":"2016","unstructured":"Huo\u00a0L, et\u00a0al. Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes. Diabetologia. 2016;59(7):1437\u201345.","journal-title":"Diabetologia"},{"issue":"15","key":"2667_CR15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani\u00a0A, et\u00a0al. Mortality and Cardiovascular Disease in Type\u00a01 and Type\u00a02 Diabetes. N\u00a0Engl J Med. 2017;376(15):1407\u201318.","journal-title":"N Engl J Med"},{"issue":"16","key":"2667_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/eurjpc\/zwab011","volume":"28","author":"KH Mak","year":"2022","unstructured":"Mak\u00a0KH, et\u00a0al. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. Eur J Prev Cardiol. 2022;28(16):1795\u2013806.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"2667_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.amjcard.2009.10.048","volume":"105","author":"M Krempf","year":"2010","unstructured":"Krempf\u00a0M, et\u00a0al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010;105(5):667\u201371.","journal-title":"Am J Cardiol"},{"issue":"16","key":"2667_CR18","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1161\/CIRCULATIONAHA.118.037454","volume":"139","author":"A Rawshani","year":"2019","unstructured":"Rawshani\u00a0A, et\u00a0al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type\u00a01 Diabetes Mellitus. Circulation. 2019;139(16):1900\u201312.","journal-title":"Circulation"},{"issue":"9","key":"2667_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.112.000908","volume":"127","author":"TM Davis","year":"2013","unstructured":"Davis\u00a0TM, et\u00a0al. Prognostic significance of silent myocardial infarction in newly diagnosed type\u00a02 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation. 2013;127(9):980\u20137.","journal-title":"Circulation"},{"issue":"1","key":"2667_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jjcc.2018.05.017","volume":"73","author":"H Soejima","year":"2019","unstructured":"Soejima\u00a0H, et\u00a0al. One quarter of total myocardial infarctions are silent manifestation in patients with type\u00a02 diabetes mellitus. J\u00a0Cardiol. 2019;73(1):33\u20137.","journal-title":"J Cardiol"},{"issue":"4","key":"2667_CR21","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.2337\/dc19-2201","volume":"43","author":"MJ Singleton","year":"2020","unstructured":"Singleton\u00a0MJ, et\u00a0al. Association of Silent Myocardial Infarction With Major Cardiovascular Events in Diabetes: The ACCORD Trial. Diabetes Care. 2020;43(4):e45\u2013e6.","journal-title":"Diabetes Care"},{"issue":"5","key":"2667_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.amjcard.2015.11.060","volume":"117","author":"B Aggarwal","year":"2016","unstructured":"Aggarwal\u00a0B, et\u00a0al. Utility of Glycated Hemoglobin for Assessment of Glucose Metabolism in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2016;117(5):749\u201353.","journal-title":"Am J Cardiol"},{"issue":"9","key":"2667_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui\u00a0MH, Aboyans\u00a0V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509\u201326.","journal-title":"Circ Res"},{"issue":"36","key":"2667_CR24","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai\u00a0L, et\u00a0al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart\u00a0J. 2024;45(36):3538\u2013700.","journal-title":"Eur Heart J"},{"issue":"2","key":"2667_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/2047487319880044","volume":"26","author":"G Buso","year":"2019","unstructured":"Buso\u00a0G, Aboyans\u00a0V, Mazzolai\u00a0L. Lower extremity artery disease in patients with type\u00a02 diabetes. Eur J Prev Cardiol. 2019;26(2):114\u201324.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"2667_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jdiacomp.2016.03.033","volume":"30","author":"NM Malyar","year":"2016","unstructured":"Malyar\u00a0NM, et\u00a0al. Amputations and mortality in in-hospital treated patients with peripheral artery disease and diabetic foot syndrome. J\u00a0Diabetes Complications. 2016;30(6):1117\u201322.","journal-title":"J Diabetes Complications"},{"issue":"24","key":"2667_CR27","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong\u00a0DG, Boulton\u00a0AJM, Bus\u00a0SA. Diabetic foot ulcers and their recurrence. N\u00a0Engl J Med. 2017;376(24):2367\u201375.","journal-title":"N Engl J Med"},{"issue":"3","key":"2667_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/ATVBAHA.119.312859","volume":"40","author":"A Behroozian","year":"2020","unstructured":"Behroozian\u00a0A, Beckman\u00a0JA. Microvascular Disease Increases Amputation in Patients With Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40(3):534\u201340.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"2667_CR29","doi-asserted-by":"publisher","first-page":"e3279","DOI":"10.1002\/dmrr.3279","volume":"36","author":"RO Forsythe","year":"2020","unstructured":"Forsythe\u00a0RO, et\u00a0al. Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral artery disease: a\u00a0systematic review. Diabetes Metab Res Rev. 2020;36(Suppl 1):e3279.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"2667_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1191\/1358863x06vm677oa","volume":"11","author":"P Lacroix","year":"2006","unstructured":"Lacroix\u00a0P, et\u00a0al. Type\u20112 diabetes and carotid stenosis: a\u00a0proposal for a\u00a0screening strategy in asymptomatic patients. Vasc Med. 2006;11(2):93\u20139.","journal-title":"Vasc Med"},{"issue":"6","key":"2667_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jfma.2021.10.005","volume":"121","author":"TW Wu","year":"2022","unstructured":"Wu\u00a0TW, et\u00a0al. Prevalences of diabetes mellitus and carotid atherosclerosis and their relationships in middle-aged adults and elders: a\u00a0community-based study. J\u00a0Formos Med Assoc. 2022;121(6):1133\u201340.","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"2667_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/dia.2019.0251","volume":"22","author":"J Lu","year":"2020","unstructured":"Lu\u00a0J, et\u00a0al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type\u00a02 Diabetes. Diabetes Technol Ther. 2020;22(2):72\u20138.","journal-title":"Diabetes Technol Ther"},{"issue":"19","key":"2667_CR33","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.21037\/atm.2019.12.153","volume":"8","author":"N Katsiki","year":"2020","unstructured":"Katsiki\u00a0N, Mikhailidis\u00a0DP. Diabetes and carotid artery disease: a\u00a0narrative review. Ann Transl Med. 2020;8(19):1280.","journal-title":"Ann Transl Med"},{"issue":"13","key":"2667_CR34","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/cvr\/cvy174","volume":"114","author":"J Raffort","year":"2018","unstructured":"Raffort\u00a0J, et\u00a0al. Diabetes and aortic aneurysm: current state of the art. Cardiovasc Res. 2018;114(13):1702\u201313.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2667_CR35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jvs.2021.10.019","volume":"75","author":"MJ Nordness","year":"2022","unstructured":"Nordness\u00a0MJ, et\u00a0al. The effect of diabetes on abdominal aortic aneurysm growth over 2\u00a0years. J\u00a0Vasc Surg. 2022;75(4):1211\u201322. e1..","journal-title":"J Vasc Surg"},{"issue":"7","key":"2667_CR36","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui\u00a0R, et\u00a0al. Heart Failure: An Underappreciated Complication of Diabetes. A\u00a0Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670\u201390.","journal-title":"Diabetes Care"},{"issue":"3","key":"2667_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2337\/diacare.28.3.612","volume":"28","author":"IS Thrainsdottir","year":"2005","unstructured":"Thrainsdottir\u00a0IS, et\u00a0al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28(3):612\u20136.","journal-title":"Diabetes Care"},{"issue":"24","key":"2667_CR38","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","volume":"138","author":"DA McAllister","year":"2018","unstructured":"McAllister\u00a0DA, et\u00a0al. Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation. 2018;138(24):2774\u201386.","journal-title":"Circulation"},{"issue":"15","key":"2667_CR39","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1053\/euhj.2000.2533","volume":"22","author":"A Mosterd","year":"2001","unstructured":"Mosterd\u00a0A, et\u00a0al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart\u00a0J. 2001;22(15):1318\u201327.","journal-title":"Eur Heart J"},{"issue":"15","key":"2667_CR40","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, et\u00a0al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N\u00a0Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"17","key":"2667_CR41","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, et\u00a0al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N\u00a0Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"},{"issue":"12","key":"2667_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, et\u00a0al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N\u00a0Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"16","key":"2667_CR43","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, et\u00a0al. Empagliflozin in Heart Failure with a\u00a0Preserved Ejection Fraction. N\u00a0Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"2667_CR44","doi-asserted-by":"crossref","unstructured":"Nakamura K, et\u00a0al. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. Int J Mol Sci. 2022;23(7).","DOI":"10.3390\/ijms23073587"},{"issue":"22","key":"2667_CR45","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","volume":"103","author":"C Iribarren","year":"2001","unstructured":"Iribarren\u00a0C, et\u00a0al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103(22):2668\u201373.","journal-title":"Circulation"},{"issue":"8","key":"2667_CR46","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.2337\/db10-0165","volume":"59","author":"K Matsushita","year":"2010","unstructured":"Matsushita\u00a0K, et\u00a0al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010;59(8):2020\u20136.","journal-title":"Diabetes"},{"issue":"8","key":"2667_CR47","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2337\/dc21-0429","volume":"44","author":"M Wamil","year":"2021","unstructured":"Wamil\u00a0M, et\u00a0al. Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type\u00a02 Diabetes: UKPDS 89. Diabetes Care. 2021;44(8):1877\u201384.","journal-title":"Diabetes Care"},{"issue":"36","key":"2667_CR48","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, et\u00a0al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"5","key":"2667_CR49","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh\u00a0K, et\u00a0al. Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. J\u00a0Am Coll Cardiol. 2019;73(5):602\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"2667_CR50","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, et\u00a0al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"6","key":"2667_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","volume":"76","author":"JE Wilcox","year":"2020","unstructured":"Wilcox\u00a0JE, et\u00a0al. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J\u00a0Am Coll Cardiol. 2020;76(6):719\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"28","key":"2667_CR52","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","volume":"44","author":"SC-DW Group","year":"2023","unstructured":"Group\u00a0SC-DW, the SCORE-Diabetes\u00a0ESCCRC. 10-year cardiovascular risk estimation in type\u00a02 diabetes in Europe. Eur Heart\u00a0J. 2023;44(28):2544\u201356.","journal-title":"Eur Heart J"},{"issue":"18","key":"2667_CR53","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1093\/eurheartj\/ehn334","volume":"29","author":"M Huelsmann","year":"2008","unstructured":"Huelsmann\u00a0M, et\u00a0al. NT-proBNP has a\u00a0high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart\u00a0J. 2008;29(18):2259\u201364.","journal-title":"Eur Heart J"},{"issue":"36","key":"2667_CR54","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints\u00a0C, et\u00a0al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart\u00a0J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"4S","key":"2667_CR55","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013S314.","journal-title":"Kidney Int"},{"issue":"2","key":"2667_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, et\u00a0al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR57","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care. 2025;48(1):S239\u2013S51.","journal-title":"Diabetes Care"},{"issue":"9","key":"2667_CR58","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani\u00a0SS, et\u00a0al. AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A\u00a0Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013e119. 2023.","journal-title":"Circulation"},{"issue":"12","key":"2667_CR59","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","volume":"2","author":"S Malik","year":"2017","unstructured":"Malik\u00a0S, et\u00a0al. Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type\u00a02 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2017;2(12):1332\u201340.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2667_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jcmg.2015.11.011","volume":"9","author":"MJ Budoff","year":"2016","unstructured":"Budoff\u00a0MJ, et\u00a0al. Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology. JACC Cardiovasc Imaging. 2016;9(2):176\u201392.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"2667_CR61","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2337\/diacare.27.8.1954","volume":"27","author":"FJ Wackers","year":"2004","unstructured":"Wackers\u00a0FJ, et\u00a0al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27(8):1954\u201361.","journal-title":"Diabetes Care"},{"issue":"15","key":"2667_CR62","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2009.476","volume":"301","author":"LH Young","year":"2009","unstructured":"Young\u00a0LH, et\u00a0al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type\u00a02 diabetes: the DIAD study: a\u00a0randomized controlled trial. JAMA. 2009;301(15):1547\u201355.","journal-title":"JAMA"},{"issue":"21","key":"2667_CR63","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1001\/jama.2014.15825","volume":"312","author":"JB Muhlestein","year":"2014","unstructured":"Muhlestein\u00a0JB, et\u00a0al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014;312(21):2234\u201343.","journal-title":"JAMA"},{"issue":"24","key":"2667_CR64","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"BDS Group","year":"2009","unstructured":"Group\u00a0BDS, et\u00a0al. A\u00a0randomized trial of therapies for type\u00a02 diabetes and coronary artery disease. N\u00a0Engl J Med. 2009;360(24):2503\u201315.","journal-title":"N Engl J Med"},{"issue":"15","key":"2667_CR65","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden\u00a0WE, et\u00a0al. Optimal medical therapy with or without PCI for stable coronary disease. N\u00a0Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.122.062714","volume":"147","author":"JS Hochman","year":"2023","unstructured":"Hochman\u00a0JS, et\u00a0al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023;147(1):8\u201319.","journal-title":"Circulation"},{"issue":"2","key":"2667_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MCA.0000000000001041","volume":"33","author":"R Shah","year":"2022","unstructured":"Shah\u00a0R, et\u00a0al. A\u00a0meta-analysis of optimal medical therapy with or without percutaneous coronary intervention in patients with stable coronary artery disease. Coron Artery Dis. 2022;33(2):91\u20137.","journal-title":"Coron Artery Dis"},{"issue":"1","key":"2667_CR68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12872-024-03997-7","volume":"24","author":"L Bi","year":"2024","unstructured":"Bi\u00a0L, et\u00a0al. An updated meta-analysis of optimal medical therapy with or without invasive therapy in patients with stable coronary artery disease. BMC Cardiovasc Disord. 2024;24(1):335.","journal-title":"BMC Cardiovasc Disord"},{"issue":"15","key":"2667_CR69","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1916370","volume":"382","author":"JA Spertus","year":"2020","unstructured":"Spertus\u00a0JA, et\u00a0al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N\u00a0Engl J Med. 2020;382(15):1408\u201319.","journal-title":"N Engl J Med"},{"issue":"38","key":"2667_CR70","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne\u00a0RA, et\u00a0al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart\u00a0J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"1S","key":"2667_CR71","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","volume":"58","author":"MS Conte","year":"2019","unstructured":"Conte\u00a0MS, et\u00a0al. Global vascular guidelines on the management of chronic limb-threatening Ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1\u2013S109.e33.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"2667_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","volume":"67","author":"J Nordanstig","year":"2024","unstructured":"Nordanstig\u00a0J, et\u00a0al. Editor\u2019s Choice\u2014European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2024;67(1):9\u201396.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"e3276","key":"2667_CR73","first-page":"1","volume":"36","author":"RJ Hinchliffe","year":"2020","unstructured":"Hinchliffe\u00a0RJ, et\u00a0al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(e3276):1.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"2667_CR74","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1001\/jama.2014.16804","volume":"313","author":"GW Weyer","year":"2015","unstructured":"Weyer\u00a0GW, Davis\u00a0AM. Screening for asymptomatic carotid artery stenosis. JAMA. 2015;313(2):192\u20133.","journal-title":"JAMA"},{"issue":"5","key":"2667_CR75","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jama.2020.26988","volume":"325","author":"USPST Force","year":"2021","unstructured":"Force\u00a0USPST, et\u00a0al. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force\u00a0Recommendation Statement. JAMA. 2021;325(5):476\u201381.","journal-title":"JAMA"},{"issue":"Suppl\u00a01","key":"2667_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00508-019-1471-z","volume":"131","author":"M Clodi","year":"2019","unstructured":"Clodi\u00a0M, et\u00a0al. Antihyperglycemic treatment guidelines for diabetes mellitus type\u00a02 (Update 2019). Wien Klin Wochenschr. 2019;131(Suppl\u00a01):27\u201338.","journal-title":"Wien Klin Wochenschr"},{"issue":"9933","key":"2667_CR77","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","volume":"383","author":"RR Holman","year":"2014","unstructured":"Holman\u00a0RR, Sourij\u00a0H, Califf\u00a0RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type\u00a02 diabetes. Lancet. 2014;383(9933):2008\u201317.","journal-title":"Lancet"},{"key":"2667_CR78","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type\u00a02 diabetes (UKPDS\u00a034). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p.\u00a0854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"issue":"15","key":"2667_CR79","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman\u00a0RR, et\u00a0al. 10-year follow-up of intensive glucose control in type\u00a02 diabetes. N\u00a0Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"9","key":"2667_CR80","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","volume":"60","author":"SJ Griffin","year":"2017","unstructured":"Griffin\u00a0SJ, Leaver\u00a0JK, Irving\u00a0GJ. Impact of metformin on cardiovascular disease: a\u00a0meta-analysis of randomised trials among people with type\u00a02 diabetes. Diabetologia. 2017;60(9):1620\u20139.","journal-title":"Diabetologia"},{"issue":"10448","key":"2667_CR81","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"AI Adler","year":"2024","unstructured":"Adler\u00a0AI, et\u00a0al. Post-trial monitoring of a\u00a0randomised controlled trial of intensive glycaemic control in type\u00a02 diabetes extended from 10\u00a0years to 24\u00a0years (UKPDS\u00a091). Lancet. 2024;404(10448):145\u201355.","journal-title":"Lancet"},{"issue":"3","key":"2667_CR82","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","volume":"13","author":"C Lamanna","year":"2011","unstructured":"Lamanna\u00a0C, et\u00a0al. Effect of metformin on cardiovascular events and mortality: a\u00a0meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"2667_CR83","doi-asserted-by":"publisher","first-page":"108001","DOI":"10.1016\/j.diabres.2020.108001","volume":"160","author":"K Zhang","year":"2020","unstructured":"Zhang\u00a0K, et\u00a0al. Cardiovascular risk following metformin treatment in patients with type\u00a02 diabetes mellitus: Results from meta-analysis. Diabetes Res Clin Pract. 2020;160:108001.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2667_CR84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40200-023-01309-y","volume":"23","author":"M Bahardoust","year":"2024","unstructured":"Bahardoust\u00a0M, et\u00a0al. Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis. J\u00a0Diabetes Metab Disord. 2024;23(1):27\u201338.","journal-title":"J Diabetes Metab Disord"},{"issue":"e14502","key":"2667_CR85","first-page":"3","volume":"38","author":"C Escobar","year":"2021","unstructured":"Escobar\u00a0C, et\u00a0al. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type\u00a02 diabetes mellitus to prevent cardiovascular events: A\u00a0systematic review. Diabet Med. 2021;38(e14502):3.","journal-title":"Diabet Med"},{"issue":"10157","key":"2667_CR86","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez\u00a0AF, et\u00a0al. Albiglutide and cardiovascular outcomes in patients with type\u00a02 diabetes and cardiovascular disease (Harmony Outcomes): a\u00a0double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"4","key":"2667_CR87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, et\u00a0al. Dapagliflozin and Cardiovascular Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2667_CR88","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Liraglutide and Cardiovascular Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2667_CR89","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Semaglutide and Cardiovascular Outcomes in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2667_CR90","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, et\u00a0al. Dulaglutide and cardiovascular outcomes in type\u00a02 diabetes (REWIND): a\u00a0double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10489","key":"2667_CR91","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca\u00a0MP, et\u00a0al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type\u00a02 diabetes (STRIDE): a\u00a0phase\u00a03b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580\u201393.","journal-title":"Lancet"},{"issue":"20","key":"2667_CR92","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire\u00a0DK, et\u00a0al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type\u00a02 Diabetes. N\u00a0Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"23","key":"2667_CR93","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer\u00a0MA, et\u00a0al. Lixisenatide in Patients with Type\u00a02 Diabetes and Acute Coronary Syndrome. N\u00a0Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"25","key":"2667_CR94","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1056\/NEJMc1714163","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman\u00a0RR, Bethel\u00a0MA, Hernandez\u00a0AF. Once-Weekly Exenatide and Cardiovascular Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2017;377(25):2502.","journal-title":"N Engl J Med"},{"issue":"22","key":"2667_CR95","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, et\u00a0al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"21","key":"2667_CR96","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Matthews\u00a0DR. Canagliflozin and Cardiovascular and Renal Events in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"key":"2667_CR97","doi-asserted-by":"crossref","unstructured":"Zinman B, et\u00a0al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2015;.","DOI":"10.1056\/NEJMoa1504720"},{"issue":"1","key":"2667_CR98","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk\u00a0N, et\u00a0al. Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type\u00a02 diabetes. Cardiovasc Diabetol. 2025;24(1):177.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2667_CR99","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen\u00a0BL, et\u00a0al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP\u20111 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type\u00a02 Diabetes and Albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"},{"issue":"23","key":"2667_CR100","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx\u00a0N, et\u00a0al. Oral Semaglutide and Cardiovascular Outcomes in People With Type\u00a02 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025;151(23):1639\u201350.","journal-title":"Circulation"},{"key":"2667_CR101","first-page":"372","volume":"m4573","author":"SC Palmer","year":"2021","unstructured":"Palmer\u00a0SC, et\u00a0al. Sodium-glucose cotransporter protein\u20112 (SGLT-2) inhibitors and glucagon-like peptide\u20111 (GLP-1) receptor agonists for type\u00a02 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;m4573:372.","journal-title":"BMJ"},{"issue":"17","key":"2667_CR102","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker\u00a0TA, et\u00a0al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type\u00a02 Diabetes Mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"11","key":"2667_CR103","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"O Vaccaro","year":"2017","unstructured":"Vaccaro\u00a0O, et\u00a0al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type\u00a02 diabetes inadequately controlled with metformin (TOSCA.IT): a\u00a0randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887\u201397.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9493","key":"2667_CR104","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy\u00a0JA, et\u00a0al. Secondary prevention of macrovascular events in patients with type\u00a02 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a\u00a0randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"3","key":"2667_CR105","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R Wilcox","year":"2007","unstructured":"Wilcox\u00a0R, et\u00a0al. Effects of pioglitazone in patients with type\u00a02 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events\u00a004). Stroke. 2007;38(3):865\u201373.","journal-title":"Stroke"},{"issue":"14","key":"2667_CR106","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan\u00a0WN, et\u00a0al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N\u00a0Engl J Med. 2016;374(14):1321\u201331.","journal-title":"N Engl J Med"},{"key":"2667_CR107","volume-title":"Fachinformation Pioglitazon-Takeda\u00ae 30\u202fmg. Fachinfo.de","author":"HT Gmb","year":"2023","unstructured":"Gmb\u00a0HT. Fachinformation Pioglitazon-Takeda\u00ae 30\u202fmg. Fachinfo.de. 2023."},{"issue":"6","key":"2667_CR108","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/sj.ki.5002442","volume":"72","author":"K Kiryluk","year":"2007","unstructured":"Kiryluk\u00a0K, Isom\u00a0R. Thiazolidinediones and fluid retention. Kidney Int. 2007;72(6):762\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"2667_CR109","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dci17-0057","volume":"41","author":"WT Cefalu","year":"2018","unstructured":"Cefalu\u00a0WT, et\u00a0al. Cardiovascular Outcomes Trials in Type\u00a02 Diabetes: Where Do We Go From Here? Reflections From a\u00a0Diabetes Care Editors\u2019 Expert Forum. Diabetes Care. 2018;41(1):14\u201331.","journal-title":"Diabetes Care"},{"key":"2667_CR110","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type\u00a02 diabetes (UKPDS\u00a033). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p.\u00a0837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"2","key":"2667_CR111","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth\u00a0W, et\u00a0al. Glucose control and vascular complications in veterans with type\u00a02 diabetes. N\u00a0Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"24","key":"2667_CR112","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"AC Group","year":"2008","unstructured":"Group\u00a0AC, et\u00a0al. Intensive blood glucose control and vascular outcomes in patients with type\u00a02 diabetes. N\u00a0Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"key":"2667_CR113","doi-asserted-by":"crossref","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study, G., et\u00a0al., Effects of intensive glucose lowering in type\u00a02 diabetes. N Engl J Med, 2008. 358(24): p.\u00a02545\u201359.","DOI":"10.1056\/NEJMoa0802743"},{"issue":"10","key":"2667_CR114","first-page":"978","volume":"373","author":"RA Hayward","year":"2015","unstructured":"Hayward\u00a0RA, et\u00a0al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2015;373(10):978.","journal-title":"N Engl J Med"},{"issue":"11","key":"2667_CR115","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"G Control","year":"2009","unstructured":"Control\u00a0G, et\u00a0al. Intensive glucose control and macrovascular outcomes in type\u00a02 diabetes. Diabetologia. 2009;52(11):2288\u201398.","journal-title":"Diabetologia"},{"issue":"25","key":"2667_CR116","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan\u00a0DM, et\u00a0al. Intensive diabetes treatment and cardiovascular disease in patients with type\u00a01 diabetes. N\u00a0Engl J Med. 2005;353(25):2643\u201353.","journal-title":"N Engl J Med"},{"issue":"3","key":"2667_CR117","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/1753-0407.12622","volume":"10","author":"A Misra","year":"2018","unstructured":"Misra\u00a0A, Bloomgarden\u00a0Z. Metabolic memory: Evolving concepts. J\u00a0Diabetes. 2018;10(3):186\u20137.","journal-title":"J Diabetes"},{"issue":"5","key":"2667_CR118","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.vph.2012.05.005","volume":"57","author":"A Ceriello","year":"2012","unstructured":"Ceriello\u00a0A. The emerging challenge in diabetes: the \u201cmetabolic memory\u201d. Vasc Pharmacol. 2012;57(5):133\u20138.","journal-title":"Vasc Pharmacol"},{"issue":"15","key":"2667_CR119","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"S Zoungas","year":"2010","unstructured":"Zoungas\u00a0S, et\u00a0al. Severe hypoglycemia and risks of vascular events and death. N\u00a0Engl J Med. 2010;363(15):1410\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"2667_CR120","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"G International Hypoglycaemia Study","year":"2019","unstructured":"International Hypoglycaemia Study\u00a0G. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):385\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2667_CR121","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti\u00a0K, et\u00a0al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type\u00a01 and type\u00a02 diabetes: a\u00a0cohort study. Diabetes Care. 2015;38(2):316\u201322.","journal-title":"Diabetes Care"},{"issue":"9844","key":"2667_CR122","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli\u00a0M, et\u00a0al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a\u00a0population-level cohort study. Lancet. 2012;380(9844):807\u201314.","journal-title":"Lancet"},{"issue":"9854","key":"2667_CR123","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox\u00a0CS, et\u00a0al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a\u00a0meta-analysis. Lancet. 2012;380(9854):1662\u201373.","journal-title":"Lancet"},{"issue":"9889","key":"2667_CR124","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort\u00a0RT, et\u00a0al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352.","journal-title":"Lancet"},{"issue":"2","key":"2667_CR125","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The\u00a0E\u2011KCG, et\u00a0al. Empagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"15","key":"2667_CR126","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, et\u00a0al. Dapagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"24","key":"2667_CR127","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, et\u00a0al. Canagliflozin and Renal Outcomes in Type\u00a02 Diabetes and Nephropathy. N\u00a0Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"2667_CR128","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner\u00a0C, et\u00a0al. Empagliflozin and Progression of Kidney Disease in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"24","key":"2667_CR129","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, et\u00a0al. Cardiovascular Events with Finerenone in Kidney Disease and Type\u00a02 Diabetes. N\u00a0Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"6","key":"2667_CR130","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos\u00a0G, et\u00a0al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type\u00a02 Diabetes. Circulation. 2021;143(6):540\u201352.","journal-title":"Circulation"},{"issue":"23","key":"2667_CR131","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, et\u00a0al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"2667_CR132","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal\u00a0R, et\u00a0al. Cardiovascular and kidney outcomes with finerenone in patients with type\u00a02 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart\u00a0J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"key":"2667_CR133","unstructured":"Bayer AG. Kerendia 10\u202fmg \/ 20\u202fmg Filmtabletten: Fachinformation. Summ Prod Charact. 2024;."},{"key":"2667_CR134","doi-asserted-by":"crossref","unstructured":"Agarwal R, et\u00a0al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type\u00a02 Diabetes. N\u00a0Engl J Med. 2025;.","DOI":"10.2337\/db25-1863-LB"},{"key":"2667_CR135","unstructured":"Solomon SD, et\u00a0al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med. 2022;."},{"issue":"21","key":"2667_CR136","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, et\u00a0al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N\u00a0Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"5","key":"2667_CR137","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K Radholm","year":"2018","unstructured":"Radholm\u00a0K, et\u00a0al. Canagliflozin and Heart Failure in Type\u00a02 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018;138(5):458\u201368.","journal-title":"Circulation"},{"issue":"12","key":"2667_CR138","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s00125-010-1906-6","volume":"53","author":"C Andersson","year":"2010","unstructured":"Andersson\u00a0C, et\u00a0al. Metformin treatment is associated with a\u00a0low risk of mortality in diabetic patients with heart failure: a\u00a0retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546\u201353.","journal-title":"Diabetologia"},{"issue":"7","key":"2667_CR139","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.amjcard.2010.05.031","volume":"106","author":"JM Evans","year":"2010","unstructured":"Evans\u00a0JM, et\u00a0al. Effect of Metformin on mortality in patients with heart failure and type\u00a02 diabetes mellitus. Am J Cardiol. 2010;106(7):1006\u201310.","journal-title":"Am J Cardiol"},{"issue":"19","key":"2667_CR140","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/heartjnl-2015-308711","volume":"102","author":"R Wurm","year":"2016","unstructured":"Wurm\u00a0R, et\u00a0al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart. 2016;102(19):1544\u201351.","journal-title":"Heart"},{"issue":"Suppl 3: p","key":"2667_CR141","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.15749","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii\u00a0GA. Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes. Diabetes Obes Metab. 2024;26(Suppl 3: p):42\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"e129","key":"2667_CR142","first-page":"12","volume":"30","author":"SE Inzucchi","year":"2007","unstructured":"Inzucchi\u00a0SE, Masoudi\u00a0FA, McGuire\u00a0DK. Metformin in heart failure. Diabetes Care. 2007;30(e129):12.","journal-title":"Diabetes Care"},{"issue":"14","key":"2667_CR143","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica\u00a0BM, et\u00a0al. Saxagliptin and cardiovascular outcomes in patients with type\u00a02 diabetes mellitus. N\u00a0Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR144","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care. 2025;48(1):S207\u2013S38.","journal-title":"Diabetes Care"},{"issue":"10","key":"2667_CR145","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/ejhf.2670","volume":"24","author":"KRH Branch","year":"2022","unstructured":"Branch\u00a0KRH, et\u00a0al. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a\u00a0post-hoc analysis from the REWIND randomized trial. Eur J Heart Fail. 2022;24(10):1805\u201312.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"2667_CR146","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","volume":"75","author":"SP Marso","year":"2020","unstructured":"Marso\u00a0SP, et\u00a0al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J\u00a0Am Coll Cardiol. 2020;75(10):1128\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2667_CR147","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley\u00a0RE, et\u00a0al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J\u00a0Am Coll Cardiol. 2024;84(17):1615\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2667_CR148","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, et\u00a0al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N\u00a0Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"15","key":"2667_CR149","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, et\u00a0al. Semaglutide in Patients with Obesity-Related Heart Failure and Type\u00a02 Diabetes. N\u00a0Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"10456","key":"2667_CR150","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, et\u00a0al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a\u00a0pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361.","journal-title":"Lancet"},{"issue":"5","key":"2667_CR151","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer\u00a0M, et\u00a0al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N\u00a0Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"16","key":"2667_CR152","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon\u00a0SD, et\u00a0al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N\u00a0Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR153","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5853\/jos.2016.00864","volume":"19","author":"SJ An","year":"2017","unstructured":"An\u00a0SJ, Kim\u00a0TJ, Yoon\u00a0BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An\u00a0Update. J\u00a0Stroke. 2017;19(1):3\u201310.","journal-title":"J Stroke"},{"issue":"4","key":"2667_CR154","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/gutjnl-2020-321585","volume":"70","author":"SE Mahady","year":"2021","unstructured":"Mahady\u00a0SE, et\u00a0al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut. 2021;70(4):717\u201324.","journal-title":"Gut"},{"issue":"1","key":"2667_CR155","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12872-016-0348-6","volume":"16","author":"A Gonzalez-Perez","year":"2016","unstructured":"Gonzalez-Perez\u00a0A, et\u00a0al. Risk of bleeding after hospitalization for a\u00a0serious coronary event: a\u00a0retrospective cohort study with nested case-control analyses. BMC Cardiovasc Disord. 2016;16(1):164.","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"2667_CR156","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaneurol.2019.1120","volume":"76","author":"WY Huang","year":"2019","unstructured":"Huang\u00a0WY, et\u00a0al. Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease: A\u00a0Systematic Review and Meta-analysis. JAMA Neurol. 2019;76(8):906\u201314.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2667_CR157","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1185\/030079907X162656","volume":"23","author":"A Lanas","year":"2007","unstructured":"Lanas\u00a0A, Scheiman\u00a0J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"16","key":"2667_CR158","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.120.045695","volume":"142","author":"AP Jacobsen","year":"2020","unstructured":"Jacobsen\u00a0AP, et\u00a0al. Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted? Circulation. 2020;142(16):1579\u201390.","journal-title":"Circulation"},{"key":"2667_CR159","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists, C., et\u00a0al., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009. 373(9678): p.\u00a01849\u201360.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"issue":"7","key":"2667_CR160","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","volume":"40","author":"AN Mahmoud","year":"2019","unstructured":"Mahmoud\u00a0AN, et\u00a0al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a\u00a0meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart\u00a0J. 2019;40(7):607\u201317.","journal-title":"Eur Heart J"},{"issue":"7","key":"2667_CR161","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","volume":"135","author":"Y Saito","year":"2017","unstructured":"Saito\u00a0Y, et\u00a0al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type\u00a02 Diabetes Mellitus: 10-Year Follow-Up of a\u00a0Randomized Controlled Trial. Circulation. 2017;135(7):659\u201370.","journal-title":"Circulation"},{"issue":"3","key":"2667_CR162","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40256-018-0313-0","volume":"19","author":"M Sugawara","year":"2019","unstructured":"Sugawara\u00a0M, et\u00a0al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a\u00a0Randomized Clinical Trial (JPPP-70). Am J Cardiovasc Drugs. 2019;19(3):299\u2013311.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"2667_CR163","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.295.3.306","volume":"295","author":"JS Berger","year":"2006","unstructured":"Berger\u00a0JS, et\u00a0al. Aspirin for the primary prevention of cardiovascular events in women and men: a\u00a0sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306\u201313.","journal-title":"JAMA"},{"issue":"16","key":"2667_CR164","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"ASC Group","year":"2018","unstructured":"Group\u00a0ASC, et\u00a0al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N\u00a0Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"key":"2667_CR165","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch\u00a0J, et\u00a0al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.","journal-title":"BMJ"},{"issue":"4","key":"2667_CR166","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","volume":"3","author":"B Scally","year":"2018","unstructured":"Scally\u00a0B, et\u00a0al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a\u00a0meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231\u201341.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2667_CR167","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FJC.0000000000000387","volume":"68","author":"JL Goldstein","year":"2016","unstructured":"Goldstein\u00a0JL, et\u00a0al. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers. J\u00a0Cardiovasc Pharmacol. 2016;68(2):121\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"24","key":"2667_CR168","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"NS Abraham","year":"2010","unstructured":"Abraham\u00a0NS, et\u00a0al. ACCF\/ACG\/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a\u00a0focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a\u00a0report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619\u201333.","journal-title":"Circulation"},{"issue":"10","key":"2667_CR169","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/ijcp.12634","volume":"69","author":"A Tran-Duy","year":"2015","unstructured":"Tran-Duy\u00a0A, et\u00a0al. Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A\u00a0systematic review and meta-analysis. Int J Clin Pract. 2015;69(10):1088\u2013111.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2667_CR170","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1097\/MJT.0000000000000637","volume":"24","author":"K Dahal","year":"2017","unstructured":"Dahal\u00a0K, et\u00a0al. Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A\u00a0Meta-Analysis of Randomized Controlled Trials. Am J Ther. 2017;24(5):e559\u2013e69.","journal-title":"Am J Ther"},{"issue":"4","key":"2667_CR171","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","volume":"162","author":"LE Targownik","year":"2022","unstructured":"Targownik\u00a0LE, Fisher\u00a0DA, Saini\u00a0SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022;162(4):1334\u201342.","journal-title":"Gastroenterology"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02667-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:54Z","timestamp":1779315174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":171,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02667-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W.\u00a0Heinzl gibt folgende Interessenkonflikte an: Honorare sowie Kongressunterst\u00fctzung von Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Sanofi-Aventis, Amgen und Bayer erhalten. M.\u00a0Resl hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit bzw. Fortbildungsunterst\u00fctzung erhalten hat: Boehringer Ingelheim, Dexcom, Abbott, Eli Lilly. C.\u00a0Steinwender gibt folgende Interessenkonflikte an: Vortr\u00e4ge und Advisory Boards f\u00fcr Medtronic, Biotronik, Abbott und Boston Scientific. P.\u00a0Fellinger gibt folgende Interessenkonflikte an: Kongressunterst\u00fctzung von Eli Lilly, Novartis und Sanofi-Aventis erhalten. T.\u00a0Steinmaurer gibt folgende Interessenkonflikte an: Honorare sowie Kongressunterst\u00fctzung von Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Sanofi-Aventis, Amgen und Mylan erhalten. C.H.\u00a0Saely hat von folgenden Firmen Honorare f\u00fcr Vortr\u00e4ge, Beratungst\u00e4tigkeit und Forschungsunterst\u00fctzung erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Genericon, Genzyme, Merck, MSD, Novartis, Novo Nordisk, Omega Pharma, Pfizer, Sanofi. F.\u00a0Hoppichler gibt folgende Interessenkonflikte an: Honorare und Projektf\u00f6rderungen von Boehringer Ingelheim, AstraZeneca, Eli Lilly, Sanofi-Aventis und Novo Nordisk erhalten. H.\u00a0Stingl hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit bzw. Fortbildungsunterst\u00fctzung erhalten: Abbott, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Novartis, Sanofi Aventis, Viatris. T.C.\u00a0Wascher gibt folgende Interessenkonflikte an: Forschungsunterst\u00fctzungen und\/oder Honorare von Amgen, AstraZeneca, Bayer Austria, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Daiichi-Sankyo. Y.\u00a0Winhofer hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit bzw. Fortbildungsunterst\u00fctzung erhalten: Abbott, Amgen, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Daiichi Sankyo, Dexcom, Eli Lilly, Novartis, Novo Nordisk, Sanofi Aventis. H.\u00a0Sourij hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amarin, Amgen, AstraZeneca, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Novartis, Sanofi-Aventis. Forschungsf\u00f6rderungen (an die MedUni Graz): Amarin, Boehringer Ingelheim, Eli Lilly und Daiichi Sankyo. B.\u00a0Paulweber gibt folgende Interessenkonflikte an: Honorare sowie Kongressunterst\u00fctzung von Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi-Aventis und Sobi erhalten. H.\u00a0Toplak gibt folgende Interessenkonflikte an: Honorare f\u00fcr Beratung und Vortragst\u00e4tigkeit von Amgen, B\u00f6hringer Ingelheim, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi; Forschungsunterst\u00fctzung von Boehringer Ingelheim, Novartis und Novo Nordisk. H.\u00a0Drexel gibt folgende Interessenkonflikte an: Advisory boards sowie consultancy bei Daiichi Sankyo, Novartis und MedMedia; Vortr\u00e4ge und Vorsitze bei Menarini, Sanofi und Novartis. T.\u00a0Stulnig gibt folgende Interessenkonflikte an: Reisekostenunterst\u00fctzung und Honoraria von Akcea, Alexion, Amgen, AstraZeneca, Biomarin, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novartis, Novo Nordisk, Sanofi; Forschungsunterst\u00fctzung von 89bio, Akcea, Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novartis, Sanofi. M.\u00a0Clodi gibt folgende Interessenkonflikte an: Vortr\u00e4ge, Studien und Beratung f\u00fcr Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Novartis, Daiichi Sankyo, Amgen, W\u00f6rwag, Sanofi, Amarin, Roche, Bayer. J.\u00a0Maier, J.\u00a0Falkensammer und B.\u00a0F\u00f6ger geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}